Headlands Technologies LLC Increases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Headlands Technologies LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 397.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,675 shares of the medical research company’s stock after purchasing an additional 1,338 shares during the period. Headlands Technologies LLC’s holdings in IQVIA were worth $329,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $33,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc boosted its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter worth approximately $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 7.8 %

NYSE IQV opened at $154.63 on Friday. The business’s fifty day simple moving average is $189.67 and its 200-day simple moving average is $204.07. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $27.26 billion, a PE ratio of 20.62, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52 week low of $154.35 and a 52 week high of $252.88.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Citigroup decreased their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Barclays reduced their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.